<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150514</url>
  </required_header>
  <id_info>
    <org_study_id>AB0103</org_study_id>
    <nct_id>NCT00150514</nct_id>
  </id_info>
  <brief_title>Effects of Sublingual Immunotherapy on Grasspollen Allergy</brief_title>
  <official_title>A Placebo Controlled, Double-Blind, Randomised Study to Assess Efficacy of Sublingual Immunotherapy in Patients With Grass Pollen Allergy Through Assessment of Its Immunological Effects on the Mucosal Tissue of the Nose.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      The objective of the study is to document the objective immunological effects of SLIT on the&#xD;
      nasal mucosa. Better understanding of these immunological pathways, in which this widely&#xD;
      practised clinical therapy is likely to work, can only benefit the overall outcome of this,&#xD;
      more patient friendly, therapy and it will demonstrate the effects of SLIT on the allergic&#xD;
      reaction, with objective parameters, in the nasal tissues showing it to be a true etiological&#xD;
      treatment of allergy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind placebo controlled evaluation of the immunological effects (decrease of IgE&#xD;
      specific cells and the decrease of Th2 mediator release, respectively increase of Th1&#xD;
      mediator release) of SLIT on the nasal mucosal tissue of adult humans with severe&#xD;
      rhinocunjunctivitis due to grass pollen allergy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date>December 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Double blind placebo controlled evaluation of the immunological effects of SLIT on the nasal mucosal tissue of adult humans with sever</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>I. Correlating immunological effects to a retrospective subjective complaint reduction.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>II. Rescue medication decrease through SLIT.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>III. Determining the effects of SLIT on decongestion.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IV. Assessment of treatment compliance.</measure>
  </secondary_outcome>
  <enrollment>38</enrollment>
  <condition>Hayfever</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oralgen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nasal biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nasal washing</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peak nasal inspiratory flow</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 and older.&#xD;
&#xD;
          2. Patients known in general practice with documented clinical history of grass pollen&#xD;
             allergy with moderate disease intensity as retrospectively derived from the use of&#xD;
             symptomatic allergy medication during the previous grass pollen season, i.e. regular&#xD;
             use of cromoglycates as nasal spray and/or eye drops, and/or regular use of anti&#xD;
             histamine tablets or sprays and/or limited use of local acting or systemically&#xD;
             administered corticosteroids.&#xD;
&#xD;
          3. Positive (ARTU) grass pollen specific skin prick test (despite negative RAST).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical history of severe asthmatic symptoms requiring inhalant therapy with daily&#xD;
             pulmonary steroids during at least 3 months a year.&#xD;
&#xD;
          2. Symptomatic perennial allergic rhinitis. Meaning perennial allergy is allowed if the&#xD;
             allergen is not present in patients' daily life (especially one month prior to&#xD;
             provocation) and if they have no apparent symptoms of this perennial allergy.&#xD;
&#xD;
          3. Other seasonal allergic rhinitis are not allowed unless it is asymptomatic during the&#xD;
             period of provocation.&#xD;
&#xD;
          4. The intention to subject the patient to surgery of the nasal cavity in the course of&#xD;
             the study.&#xD;
&#xD;
          5. Previous immunotherapy.&#xD;
&#xD;
          6. Negative (ARTU) grass pollen specific skin prick test (despite positive RAST).&#xD;
&#xD;
          7. Contraindications to sublingual immunotherapy, i.e.:&#xD;
&#xD;
               -  Malignancies and serious disorders of the oral cavity&#xD;
&#xD;
               -  History of status asthmaticus and anaphylactic shock&#xD;
&#xD;
               -  Aggressively developing asthmatic symptoms&#xD;
&#xD;
               -  Serious chronic inflammations, chronic disorders associated with fever,&#xD;
                  particularly of the bronchial tubes&#xD;
&#xD;
               -  Irreversible, secondary changes in reactive organs (emphysema, bronchiectasis)&#xD;
&#xD;
               -  Auto immune diseases and immunodeficiency&#xD;
&#xD;
               -  Concurrent therapy involving immunosuppressives&#xD;
&#xD;
               -  Systemic and collagen diseases&#xD;
&#xD;
               -  Tuberculosis of the lung and tuberculosis&#xD;
&#xD;
               -  Serious psychological disorders&#xD;
&#xD;
               -  Documented hypersensitivity to glycerol&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  Serious cardiovascular disease&#xD;
&#xD;
               -  Usage of b -blockers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K Ingels, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud university hospital</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2003</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>September 7, 2005</last_update_submitted>
  <last_update_submitted_qc>September 7, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2005</last_update_posted>
  <keyword>nasal biopsy grasspollen sublingual immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

